[1] Lee S.Dexmedetomidine: present and future directions[J]. Korean Journal of Anesthesiology, 2019, 72(4): 323-330. [2] Mahmoud M, Mason KP.Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations[J]. British Journal of Anaesthesia, 2015, 115(2): 171-182. [3] Nguyen V, Tiemann D, Park E, et al.Alpha-2 Agonists[J]. anesth-esiology Clinics, 2017, 35(2): 233-245. [4] Yang B, Zhao YL, Zhou WB, et al.Comparison of sedative effect and safety of midazolam and dexmedetomidine on ICU patients with long-term mechanical ventilation[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 140-143. [5] Tian ZT, Huang H.The clinical effect of dexmedetomidine in ventilated patients sedation[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2010, 7(9): 515-517. [6] Weerink MAS, Struys MMRF, Hannivoort LN, et al.Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine[J]. Clinical Pharmacokinetics, 2017, 56(8): 893-913. [7] Pickard A, Davies P, Birnie K, et al.Systematic review and meta-analysis of the effect of intraoperative alpha(2)-adrenergic agonists on postoperative behaviour in children[J]. British Journal of Anaesthesia, 2014, 112(6): 982-990. [8] Jiang Y, Xia M, Huang Q, et al.Protective effect of dexmedetomidine against organ dysfunction in a two-hit model of hemorrhage/resuscitation and endotoxemia in rats[J]. Brazilian Journal of Medical and Biological Research, 2019, 52(3): e7905. [9] Endesfelder S, Makki H, von Haefen C, et al. Neuroprotective effects of dexmedetomidine against hyperoxia-induced injury in the developing rat brain[J]. PLoS One, 2017, 12(2): e0171498. [10] Brust JCM.Neurological aspects of substance abuse[M]. 2nd ed. Philadelphia: Elsevier Butterworth Heinemann, 2004: 201-204. [11] Uskur T, Barlas MA, Akkan AG, et al.Dexmedetomidine induces conditioned place preference in rats: Involvement of opioid receptors[J]. Behavioural Brain Research, 2016, 296: 163-168. [12] Chen Y,Wu N,Cao DN, et al.Influence of different training time on formation of methamphetamine self-administration in rats[J]. Chinese Journal of Pharmacology Toxicology(中国药理学与毒理学杂志), 2012, 26(3): 347-352. [13] National Medical Products Administration. Guideline on the non-clinical investigation of the dependence potential of drugs[S]. 2007. [14] Food and Drug Administration. Guidance for industry: assessment of abuse potential of drugs[S]. 2017. [15] European Medicines Agency.Guideline on the non-clinical investigation of the dependence potential of medicinal products[S]. 2006. [16] Huang JH, Huang XH, Chen ZY, et al.Dose conversion among different animals and healthy volunteers in pharmacological study[J]. Chinese Journal of Clinical Pharmacology and Therapeutics(中国临床药理学与治疗学), 2004, 9(9): 1069-1072. [17] Camí J, Farré M.Mechanisms of disease drug addiction[J]. N Engl J Med, 2003, 349: 975-986. [18] Havlickova T, Charalambous C, Lapka M, et al.Ghrelin receptor antagonism of methamphetamine-induced conditioned place preference and intravenous self-administration in rats[J]. Internat-ional Journal of Molecular Sciences, 2018, 19(10): 2925-2946. [19] Mona A, Erin MP, Adam KK, et al.Methamp-hetamine self-admin-istration in a runway model of drug-seeking behavior in male rats[J]. Pharmacology, Biochemistry, and Behavior, 2018, 175: 27-32. |